Full Press Release Details
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP)
IMMUTEP ANNOUNCES AUSTRALIAN PATENT GRANTED FOR EFTILAGIMOD ALPHA
IN CHEMO-IMMUNOTHERAPY
AUSTRALIA 21 June 2019 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and
autoimmune diseases, is pleased to announce the grant of a new patent (number 2014368420) entitled Combined Preparations for the Treatment of Cancer by the Australian Patent Office.
This Australian patent follows the recent grant of the corresponding European patent (announced 23 May 2019) and protects Immutep s intellectual
property relating to combined therapeutic preparations comprising its lead active immunotherapy candidate eftilagimod alpha ( efti or IMP321 ) and a chemotherapy agent. The chemotherapy agent is either a platinum-based
anti-neoplastic agent, such as oxaliplatin or carboplatin, or a topoisomerase I inhibitor, such as topotecan.
The new patent again highlights the broad
potential of efti as an immunostimulant and provides patent protection in Australia for a range of novel and highly relevant chemo-immunotherapies featuring efti that may be pursued in the future.
The patent expiry date is 19 December 2034.
Immutep is a globally active biotechnology company that is a leader in the development of immunotherapeutic products for the treatment of
cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
Immutep s current lead product is eftilagimod alpha ( efti or IMP321 ), a soluble LAG-3Ig
fusion protein based on the LAG-3 immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase IIb clinical trial as a
chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT02614833); a Phase II clinical trial referred to as TACTI-002 (Two ACTive Immunotherapies) to evaluate a
combination of efti with KEYTRUDA (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); a Phase I clinical trial referred to as INSIGHT-004 to evaluate a combination of efti with avelumab (clinical trials.gov identifier NCT03252938); and a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel (clinicaltrials.gov
identifier NCT02676869).
Additional LAG-3 products, including antibodies, for immune response modulation in
autoimmunity and cancer are being developed by Immutep s large pharmaceutical partners. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
Immutep is listed on the Australian Securities
Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Further information can be found on the Company s website www.immutep.com or
Australian Investors/Media:
Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com
Jay Campbell, Chief Business Officer,
+1 (917) 860-9404; jay.campbell@immutep.com
Garth Russell, LifeSci Advisors
+1 (646) 876-3613; garth@lifesciadvisors.com